Browse the evidence

Semaglutide (≥0.2 mg once weekly) demonstrates statistically significant weight loss compared to liraglutide 3.0 mg in patients with obesity without diabetes.

For obese adults without diabetes, semaglutide doses of 0.2 mg or higher (weekly) result in greater weight loss than liraglutide 3.0 mg (daily).

Incretin-based therapies (GLP-1 and GLP-1/GIP dual agonists) provide superior glycemic control and weight loss compared to basal insulin in Type 2 Diabetes, with lower hypoglycemia risk.

If you have Type 2 Diabetes and need an injection, ask about GLP-1 or GLP-1/GIP agonists (like Semaglutide or Tirzepatide) before starting insulin. These drugs lower blood sugar better, help you lose weight, and carry a lower risk of dangerous low blood sugar events, though you may experience temporary stomach upset.

Anti-obesity medications (AOMs) combined with lifestyle modifications produce greater and more sustained weight loss (5-23%) compared to lifestyle changes alone, with specific agents like semaglutide and tirzepatide showing superior efficacy.

If you have obesity, lifestyle changes alone are often insufficient for long-term success due to biological factors. FDA-approved medications like semaglutide or tirzepatide, when combined with lifestyle changes, can produce significant weight loss (16-23%). These medications are intended for long-term use. Discuss with your doctor if you are a candidate, considering potential side effects and costs.

Achieving 5-10% weight loss through any method (including medication) is associated with significant improvements in obesity-related comorbidities, including type 2 diabetes prevention, cardiovascular risk reduction, and NAFLD resolution.

You do not need to lose a massive amount of weight to see health improvements. Losing just 5-10% of your body weight can significantly reduce your risk of type 2 diabetes, heart disease, and other obesity-related conditions. Focus on this achievable goal.

Laparoscopic sleeve gastrectomy (LSG) provides 60–70% excess weight loss and 50–60% type 2 diabetes remission at 5–7 years, with efficacy comparable to Roux-en-Y gastric bypass (RYGB) and superior safety for super-obese patients (BMI > 60).

Sleeve gastrectomy is currently the most common and effective surgical option for severe obesity, offering significant long-term weight loss and diabetes remission rates comparable to more complex bypass surgeries, with a strong safety profile especially for patients with very high BMI.

Preoperative and postoperative pharmacotherapy with GLP-1 agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) significantly enhances weight loss outcomes and reduces weight regain after bariatric surgery.

Using GLP-1 or dual agonists like semaglutide or tirzepatide before or after bariatric surgery can significantly boost weight loss results and prevent the common problem of weight regain, offering a powerful tool for long-term metabolic health.

GLP-1 receptor agonists (semaglutide 2.4 mg/week, tirzepatide 15 mg/week) produce significant weight loss (10–21%) and metabolic improvements in adults with obesity, though outcomes are limited by gastrointestinal side effects and long-term adherence challenges.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss (10-21%) and improving metabolic health. They work by slowing digestion and reducing appetite. Expect gastrointestinal side effects like nausea, which often improve over time. These drugs require ongoing use and can be expensive, so discuss insurance coverage and side effect management with your doctor.

Incretin-based therapies (GLP-1 and dual GIP/GLP-1 receptor agonists) administered for 12 months in adults with obesity and type 2 diabetes significantly reduce body weight, improve glycemic control, and provide multi-organ protection (cardiovascular, renal, and hepatic).

If you have obesity and type 2 diabetes, incretin-based medications (like semaglutide or tirzepatide) are highly effective for losing weight (average 10.7%), lowering blood sugar, and protecting your heart, kidneys, and liver. These benefits are consistent across different healthcare settings in Latin America. Discuss these options with your doctor, especially if you are concerned about injection frequency, as oral alternatives are emerging.

Dual and triple incretin agonists (e.g., tirzepatide, retatrutide) offer superior weight loss and glycemic control compared to single GLP-1 agonists.

Newer medications that target multiple hormones (like tirzepatide and retatrutide) are showing even greater weight loss and blood sugar control than older GLP-1 drugs. While promising, they require careful monitoring for long-term safety. These options may be considered if single-agonist therapies are insufficient.

Multidisciplinary follow-up integrating pharmacotherapy, psychology, and nutrition significantly improves therapeutic adherence, mental health outcomes, and weight loss maintenance compared to pharmacotherapy alone.

To maximize your weight loss success and mental well-being, combine medication with regular visits to a multidisciplinary team including doctors, psychologists, and nutritionists. This integrated approach improves adherence and reduces psychological risks.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to semaglutide and other GLP-1 receptor agonists in patients with type 2 diabetes.

If you have Type 2 Diabetes and struggle with weight loss, Tirzepatide (brand name Tirzetta in Russia) is currently the most effective incretin-based treatment available. It works by mimicking two gut hormones (GIP and GLP-1) to improve blood sugar control and promote significant weight loss. Treatment starts with a low dose (2.5 mg weekly) to minimize side effects, then increases every 4 weeks up to 15 mg as needed. It is administered via a user-friendly auto-injector once a week alongside a calorie-controlled diet and exercise.

Combination therapies involving GLP-1 receptor agonists (GLP-1RAs) and insulin, or comprehensive metabolic interventions including metformin, significantly increase diabetes remission rates compared to standard care.

Ask your doctor about a short-term (12-week) intensive program combining lifestyle changes, insulin, GLP-1 medication, and metformin. This aggressive approach can double your chances of reversing diabetes and potentially stop all medications long-term.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant potential for achieving prediabetes and type 2 diabetes remission through superior glycemic control and weight loss compared to other GLP-1RAs.

Ask your doctor about tirzepatide, a dual-acting medication that targets both GIP and GLP-1 receptors. It has shown exceptional results in achieving remission and significant weight loss, potentially offering a path to stopping other diabetes medications.

Tirzepatide, a dual GIP/GLP-1 agonist, achieves greater weight loss (up to 22.5%) than GLP-1RAs alone, making it the most effective pharmacological weight loss therapy currently available.

If standard GLP-1 drugs aren't enough, ask your doctor about tirzepatide. It targets two hormones (GLP-1 and GIP) to help you lose more weight (up to 22.5%) than GLP-1 drugs alone. It is taken once weekly. Like other drugs in this class, it may cause digestive issues, but it is currently the most effective non-surgical medication for weight loss.

Post-myocardial infarction patients with overweight/obesity and high-risk prediabetes (HbA1c 6.0-6.4%) face a 54% five-year risk of progressing to type 2 diabetes, making them the highest-priority candidates for semaglutide treatment.

If you have had a heart attack and are overweight, getting your HbA1c checked is critical. If it is between 6.0% and 6.4%, your risk of developing full-blown diabetes within five years is over 50%. For this specific group, treatment with semaglutide (2.4 mg weekly) is highly efficient at preventing diabetes, with fewer than three people needing treatment to save one from diabetes. This makes it a priority intervention for this subgroup.

Injectable dual incretin receptor agonists (tirzepatide) produce superior mean weight loss (20.1 kg) compared to GLP-1 receptor agonists (semaglutide 14.9 kg, liraglutide 8.4 kg) in adults with overweight or obesity.

If you have obesity (BMI ≥25), injectable medications like tirzepatide, semaglutide, or liraglutide are significantly more effective for weight loss than lifestyle changes alone. Tirzepatide offers the highest weight loss, while semaglutide balances efficacy and tolerability. Liraglutide is a moderate option, potentially suitable for those who prefer daily dosing or have lower tolerance for side effects. Discuss individual factors with your provider.

Liraglutide 3 mg daily is an effective pharmacological intervention for chronic weight management, producing a mean 5.2 kg placebo-subtracted weight loss at 1 year, with generic availability potentially improving cost-effectiveness in resource-limited settings.

If you have obesity and meet the BMI criteria, ask your doctor about liraglutide. It is a daily injection that helps suppress appetite and has been shown to help people lose an average of 5.2 kg more than placebo. Generic versions may be available, making it more affordable in some regions.

Lifestyle modifications, specifically calorie restriction of 500-750 kcal/day and ≥ 150 minutes of exercise per week, are the first-line treatment for obesity, though long-term maintenance is challenging without pharmacological or surgical support.

Start with a daily calorie deficit of 500-750 kcal and aim for at least 150 minutes of exercise per week. This is the first step in managing obesity. Remember, long-term success is often about finding a sustainable lifestyle you can stick to, rather than a specific 'magic' diet.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces clinically significant, dose-dependent reductions in body weight, HbA1c, systolic blood pressure, and atherogenic lipids (LDL, VLDL, triglycerides) with high consistency across trials.

Orforglipron is an oral medication that helps reduce weight, blood sugar, blood pressure, and bad cholesterol. It works by mimicking a gut hormone (GLP-1). You take one pill a day. It can cause stomach issues like nausea, but doctors can help manage this by starting with a low dose and increasing it slowly. It is designed for people with obesity or type 2 diabetes who want to avoid injections.

Triple receptor agonists (retatrutide) produce the highest magnitude of weight loss reported to date in pharmacotherapy for obesity, surpassing dual and single GLP-1 agonists.

Retatrutide is currently the most effective drug for weight loss in this class, working by targeting three hormonal pathways (GLP-1, GIP, and glucagon). It is administered once weekly. Expect significant weight loss, but also expect gastrointestinal side effects like nausea during the initial weeks, which typically subside.

Intragastric balloons (Obalon, Orbera, ReShape Duo) provide temporary weight loss (12-25% EWL) when combined with lifestyle modifications.

Intragastric balloons are temporary devices placed in the stomach to help with weight loss. They work by taking up space, making you feel full sooner. Clinical trials show they can lead to 12-25% excess weight loss when combined with lifestyle changes, significantly outperforming lifestyle changes alone. They require an endoscopic procedure and are typically removed after 6 months.

Tirzepatide (10 mg and 15 mg) provides statistically superior weight reduction and waist circumference reduction compared to semaglutide (2.4 mg) and liraglutide (3 mg) in patients with obesity or overweight without type 2 diabetes.

For patients with obesity or overweight without type 2 diabetes, Tirzepatide (10mg and 15mg doses) administered once weekly, alongside lifestyle changes, achieves significantly greater weight loss and waist circumference reduction than Semaglutide (2.4mg) or Liraglutide (3mg). The safety profile is generally comparable across all three treatments.

Incretin polyagonists (dual and triple agonists) produce weight loss and metabolic improvements comparable to, or approaching, those of bariatric surgery, serving as a potent non-surgical alternative.

If you have obesity and want significant weight loss without surgery, incretin polyagonists (like tirzepatide or retatrutide) are now a viable, highly effective medical option. They work by mimicking gut hormones to reduce appetite and improve metabolism. While they require weekly injections (or soon, oral pills), they can achieve weight loss results similar to bariatric surgery. Expect some initial stomach upset, which usually fades as your body adjusts. Consult a doctor to see if you are a candidate.

Preservation of lean mass during GLP-1/GIP-induced weight loss requires high-quality protein distribution (1.2–1.5 g/kg/day) and resistance exercise to mitigate sarcopenia and maintain oncologic treatment tolerance.

To prevent muscle loss while on GLP-1/GIP drugs, eat 1.2–1.5 grams of protein per kilogram of body weight daily, spread across meals, and engage in regular resistance exercise.